Paraguay Medical Device Registration: Automatic Renewal Procedure and Dossier Requirements (Article 12)
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
- Article 12: the renewal of the NSO and of the sanitary registration is processed through the simplified automatic renewal procedure (procesos simplificados de renovación automática). The word automatic describes the procedural track, not an exemption from documentation.
- The renewal dossier must contain eight document sets (a–h): a) evidence of the quality system; b) a sworn declaration of product changes in accordance with Annex IV; c) a national or international tecnovigilancia report; d) labels and instructions for use in Spanish; e) a finished-product quality control certificate or a conformity certificate issued by a notified body; f) stability studies; g) outsourcing contracts or evidence of the contractual relationship; h) for imported products, additionally the CLV and the letter of agency powers or distribution authorization.
- Article 16 of the Instructivo adds that the renewal filing must declare the technical and administrative information notified or approved as of the filing date, while the other approved fields must not be altered.
- A renewal does not change the approved substantive content of the registration. Where a modification is needed, it must be routed through the change procedure of Article 13, not introduced quietly through the renewal file.
2. Legal basis
| Instrument | Number / reference | Date | Provisions |
|---|---|---|---|
| Resolution establishing the requirements for market authorization of medical devices | Resolución DINAVISA N° 226/2024 | 2024-08-27; Article 36: in force as of 2024-09-16 | Article 12, inc. a)–h); Annex IV |
| Submission manual and guideline for applications | Instructivo ITR–DGRS-002, Versión 02 | 2024-09-09 | Article 16 |
Together these two instruments define both the content and the discipline of a Paraguay renewal. Resolution 226/2024 fixes the eight-item document set and anchors item b) to Annex IV, while the Instructivo governs how the electronic filing interacts with the data already approved in the system. Both were issued in the same regulatory generation and must be read side by side, because a dossier that satisfies the resolution but mishandles the field-level declaration rules of the Instructivo can still be returned for correction.
The eight-item list is exhaustive rather than illustrative: each lettered item corresponds to a specific evidence stream, from the quality system under item a) to the import-specific documents under item h). Because every item carries its own validity, the practical difficulty of a Paraguay renewal is less about drafting and more about synchronization: at the moment of filing, eight independent clocks must all show valid certificates, current labels and recent vigilance reporting at once.
3. Expert insights
Insight one: automatic applies to the procedure, not to the conditions. Article 12 uses the label renovación automática, but the document list is as heavy as the one for initial registration, with eight sets of documents (a–h), each of which must be valid at the time of filing. Interpreting automatic renewal as expiry-followed-by-automatic-extension leads directly to late preparation. Companies that wait until the final quarter before expiry to begin assembling the dossier routinely discover that quality system evidence, quality control certificates or stability studies have lapsed and cannot be regenerated quickly. The correct reading is procedural: renewal runs on a simplified track, but every substantive condition of the original registration must still be demonstrated afresh.
Insight two: the Annex IV sworn declaration of changes is the core renewal document. Item b) requires a sworn declaration covering the changes the product has undergone and that DINAVISA has approved. This provision ties the renewal to the change ledger: if the change records of the past 10 years are incomplete, an accurate declaration cannot be made at renewal. A gap in the ledger is not merely an internal housekeeping problem; it becomes a legal exposure, because the declaration is sworn. Maintaining the ledger contemporaneously, with one entry per approved change and a reference to the corresponding DINAVISA notification or authorization, is what keeps the renewal declaration short, truthful and easy to defend.
Insight three: item c) links post-market vigilance directly to renewal. The renewal list requires a national or international tecnovigilancia report, the most Paraguay-specific item in Article 12. It means that a product without vigilance records can face a documentation gap at renewal, because the obligation is not conditional on adverse events having occurred. The report requirement is discussed in depth in article 43 of this series; at renewal-planning level, the practical message is that the vigilance archive must be built from the first year of the certificate, not reconstructed in the final months before expiry.
4. Practical recommendations
- Maintain a ten-year change ledger that records every declared and approved change with its date and DINAVISA reference. This ledger is the working paper for the Annex IV sworn declaration and should be updated at the moment each change is approved, not retroactively.
- Assign an owner and a refresh point to each of the eight renewal items a–h, paying particular attention to the validity periods of the quality system evidence under item a) and the quality control or conformity certificate under item e), which are the items most likely to lapse unnoticed.
- Open the vigilance file in the first year of the certificate and archive it annually, so the report required under item c) exists as a by-product of routine compliance rather than a last-minute reconstruction exercise.
- At filing, update only the fields that genuinely need to change and keep every other field identical to the approved information, as required by Article 16 of the Instructivo. Silent edits to unrelated approved data are a common and avoidable cause of objections.
The field-level rule of Article 16 of the Instructivo rewards companies whose approved data are already clean. A renewal filing that touches nothing except what truly changed is reviewed faster and challenged less, which is one more reason to keep the platform record accurate throughout the certificate life rather than only in the months before renewal.
5. Verification checklist
- □ A ten-year change ledger has been established as the working paper for the Annex IV declaration
- □ Renewal items a–h each have a named owner
- □ The quality system certificate and the QC certificate are within their validity periods
- □ The tecnovigilancia report file has been opened and archived
- □ For imported products, an updated CLV and authorization letter are available
Regulatory information verified as of October 29, 2026.
GRZAN provides registration and post-market compliance support for medical device manufacturers, importers and authorized representatives in Paraguay. For assistance with renewal dossiers, change ledgers or any other regulatory matter, contact info@grzanglobal.com.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us